2021 IPO
Miromatrix Medical Stock
Biological human organ development
Sign up today and learn more about Miromatrix Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Miromatrix Medical Stock
Miromatrix Medical is a biotechnology company engaged in the development of fully biological human organs and organ-derived biological products to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization or recellularization technology, as well as organ-derived biological products for applications such as soft tissue reinforcement and advanced wound care. The company was founded in 2009 and is based in Eden Prairie, Minnesota.
Investors
National Institute of Diabetes and Digestive and Kidney Diseases
Brightstone Venture Capital
Funding History
| December 2011 | $2.0M |
|---|---|
| July 2012 | $5.3M |
| October 2013 | $5.0M |
| May 2014 | $6.1M |
| August 2015 | $23.3M |
| July 2018 | $15.7M |
| November 2019 | $2.0M |
Management
President and CEO
Jeff Ross, Ph.D
Vice-President of Research and Development
Thomas Gilbert, Ph.D
Press
EquityZen Recognized As:
